Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hisashi Higuchi

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Human Psychopharmacology|November 21, 2007
Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipranKeizo Yoshida, Hisashi Higuchi, Hitoshi Takahashi, et al.
The Journal of ECT|August 28, 2009
Predictors of response to electroconvulsive therapy obtained using the three-factor structure of the Montgomery and Asberg Depression Rating Scale for treatment-resistant depressed patientsMioto Okazaki, Keiichiro Tominaga, Hisashi Higuchi, et al.
Psychopharmacology|April 19, 2003
Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patientsGisa Gerstenberg, Toshiaki Aoshima, Takashi Fukasawa, et al.
Therapeutic Drug Monitoring|July 29, 2003
Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patientsGisa Gerstenberg, Toshiaki Aoshima, Takashi Fukasawa, et al.
Human Psychopharmacology|May 27, 2003
Milnacipran plasma levels and antidepressant response in Japanese major depressive patientsHisashi Higuchi, Keizo Yoshida, Hitoshi Takahashi, et al.
Neuropsychobiology|July 30, 2003
Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamineKeizo Yoshida, Shingo Naito, Hitoshi Takahashi, et al.
The American Journal of Psychiatry|September 1, 2004
Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphismsKeizo Yoshida, Hitoshi Takahashi, Hisashi Higuchi, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 5, 2002
No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatmentHitoshi Takahashi, Keizo Yoshida, Kenich Ito, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 31, 2002
Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patientsKeizo Yoshida, Kenichi Ito, Kazuhiro Sato, et al.
Neuropsychobiology|November 8, 2002
Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorderKazuhiro Sato, Keizo Yoshida, Hitoshi Takahashi, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Human Psychopharmacology|November 21, 2007
Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipranKeizo Yoshida, Hisashi Higuchi, Hitoshi Takahashi, et al.
The Journal of ECT|August 28, 2009
Predictors of response to electroconvulsive therapy obtained using the three-factor structure of the Montgomery and Asberg Depression Rating Scale for treatment-resistant depressed patientsMioto Okazaki, Keiichiro Tominaga, Hisashi Higuchi, et al.
Psychopharmacology|April 19, 2003
Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patientsGisa Gerstenberg, Toshiaki Aoshima, Takashi Fukasawa, et al.
Therapeutic Drug Monitoring|July 29, 2003
Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patientsGisa Gerstenberg, Toshiaki Aoshima, Takashi Fukasawa, et al.
Human Psychopharmacology|May 27, 2003
Milnacipran plasma levels and antidepressant response in Japanese major depressive patientsHisashi Higuchi, Keizo Yoshida, Hitoshi Takahashi, et al.
Neuropsychobiology|July 30, 2003
Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamineKeizo Yoshida, Shingo Naito, Hitoshi Takahashi, et al.
The American Journal of Psychiatry|September 1, 2004
Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphismsKeizo Yoshida, Hitoshi Takahashi, Hisashi Higuchi, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 5, 2002
No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatmentHitoshi Takahashi, Keizo Yoshida, Kenich Ito, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 31, 2002
Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patientsKeizo Yoshida, Kenichi Ito, Kazuhiro Sato, et al.
Neuropsychobiology|November 8, 2002
Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorderKazuhiro Sato, Keizo Yoshida, Hitoshi Takahashi, et al.
Pageof 6